Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal

A new United States-based biotechnology company named Sentivera has emerged following a significant financial and strategic arrangement. According to reports from Fierce Biotech and BioSpace, Sentivera was founded by backers of Metsera, specifically Population Health Partners and ARCH Venture Partners. The company's launch is centered around an exclusive license agreement with Haisco, a Chinese pharmaceutical entity. This deal involves a pre-clinical drug targeting inflammatory diseases, with the total potential value of the agreement reaching up to $1.5 billion. Coverage of the event is widespread across financial and industry-specific outlets.

Investing.com and TradingView emphasize the transactional nature of the deal, noting that Haisco has licensed the pre-clinical asset to the US venture. Endpoints News frames the development as part of a broader "China blitz" involving ARCH and Population Health. BioSpace further specifies that the collaboration is intended to form an immunology-focused biotech entity, leveraging American venture capital to advance the development of the drug licensed from the Chinese firm. Contextually, this move highlights a strategic bridge between Chinese pharmaceutical research and American venture capital. The involvement of ARCH Venture Partners and Population Health Partners indicates a coordinated effort by these specific backers to enter the immunology space through a partnership with Haisco.

By securing a pre-clinical drug, Sentivera enters the market with a high-value asset already in place, moving from inception to a multi-billion dollar deal structure simultaneously. This reflects a trend of US ventures seeking specialized assets from international markets to seed new biotech companies. Moving forward, the industry will monitor the progression of the pre-clinical drug as it moves toward further development. Because the deal is structured as an exclusive license agreement, the focus will remain on Sentivera's ability to advance the asset through the regulatory pipeline. The specific milestones that will trigger the full $1.5 billion payment are not detailed in the current coverage, but the partnership between Haisco and the American VCs establishes a clear financial framework for the immunology biotech's early operations.